[Therapeutic effect of anti-radiation spray on preventing and treating oral mucositis after hematopoietic stem cell transplantation].

PURPOSE: To explore the clinical efficacy of radiation-resistant liquid wound dressing in preventing and treating oral mucositis (OM) after haematopoietic stem cell transplantation (HSCT).

METHODS

A total of 68 patients who developed OM after HSCT at Xuanwu Hospital, Capital Medical University from January 2019 to June 2024 were selected and divided into the control group (n=40, standard oral care) and experimental group (n=28, Kangfu Pen combined with standard oral care) according to the type of intervention methods. The onset time and duration of OM, incidence of OM at different grades, and incidence of dry mouth and other related symptoms were compared between the two groups. Changes in the numerical rating scale (NRS) of pain, serum inflammatory factors [C-reactive protein (CRP) and procalcitonin (PCT)] levels, and body mass index (BMI) were recorded from 3 days before intervention to 21 days after transplantation.

RESULTS

The incidence of grade Ⅱ-Ⅳ OM in the experimental group (35.7%) was significantly lower than that in the control group (70.0%, P=0.046); the onset time of OM in the experimental group was significantly later, and the duration was significantly shorter than those in the control group (P＜0.001). The incidence of dry mouth in the experimental group (7.2%) was significantly lower than that in the control group (27.5%, P=0.036), and the decrease in BMI was significantly smaller than that in the control group (P＜0.001). There were no significant differences in NRS scores, CRP, or PCT levels between the two groups 3 days before intervention (P＞0.05); the above indicators in both groups reached the highest values on day 7 after transplantation. The NRS scores, CRP and PCT levels in the experimental group were significantly lower than those in the control group on days 3, 7, 14 and 21 after transplantation (P＜0.05). No adverse reactions occurred in either group.

CONCLUSIONS

Kangfu Pen is safe and effective in preventing and treating OM after HSCT, and can improve patients' quality of life. Its mechanism of action may be related to inhibiting the expression of inflammatory factors.